Synergistic effects of epoxyazadiradione (EAD) and paclitaxel against triple‐negative breast cancer cells
Fundamental & Clinical Pharmacology · 2024
DOI: 10.1111/fcp.13000 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2024. Verfasst von Kunnathully Sudhan Sijisha und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry Section, Agro-Processing and Technology Division, CSIR-National Institute for Interdisciplinary Science and Technology (CSIR-NIIST), Thi…. Hauptthemen laut MEDLINE: Paclitaxel, Triple Negative Breast Neoplasms, Drug Synergism, Apoptosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: DST-SERB.
Abstract (Originalsprache)
Background
Triple‐negative breast cancer (TNBC) is the most aggressive and chemo‐resistant form of breast cancer subtype, and chemotherapy is a vital treatment option for that. Paclitaxel is an effective chemo drug for TNBC. However, in clinical settings, paclitaxel has adverse side effects. The synergistic combination is the most promising method for overcoming undesirable toxicity and achieving a beneficial therapeutic outcome. Previous reports, including our study, showed certain anticancer potential of epoxyazadiradione (EAD), the neem limonoid, in different types of cancer cells, including TNBC.
Objective
This study was designed to investigate the possible synergistic effects of EAD and paclitaxel against TNBC cells.
Methods
We examined the effects of EAD and paclitaxel alone and in combination in MDA‐MB 231 cells, and the percentage cytotoxicity was used to calculate synergism. Characteristic apoptotic changes were observed by visualizing cellular morphology, nuclear fragmentation and membrane integrity. We further estimated anti‐migratory potential of experimental compounds by wound healing assay. The reduction in inflammation during combinatorial treatment was evaluated by observing NF‐κB translocation.
Results
The combined treatment with EAD (5 μM) and paclitaxel (5 nM), which were used at doses lower than their individual IC 50 concentrations, showed a synergistic effect in MDA‐MB‐231 cells. This combination effectively induced apoptosis and antimigration and reduced the inflammatory reactions induced by the higher dose of paclitaxel.
Conclusion
To conclude, EAD could be the drug of choice for combined treatment with paclitaxel in a chemotherapy regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biochemistry Section, Agro-Processing and Technology Division, CSIR-National Institute for Interdisciplinary Science and Technology (CSIR-NIIST), Thiruvananthapuram, Kerala, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
ORCID-Profile: Sulochana Priya
Förderung
- DST-SERB
Zitieren
APA
Sijisha, K. S., Anusha, R., & Priya, S. (2024). Synergistic effects of epoxyazadiradione (EAD) and paclitaxel against triple‐negative breast cancer cells. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.13000
Vancouver
Sijisha KS, Anusha R, Priya S. Synergistic effects of epoxyazadiradione (EAD) and paclitaxel against triple‐negative breast cancer cells. Fundamental & Clinical Pharmacology. 2024. doi:10.1111/fcp.13000
BibTeX
@article{Sijisha2024,
author = {Sijisha, Kunnathully Sudhan and Anusha, Rajitha and Priya, Sulochana},
title = {Synergistic effects of epoxyazadiradione (EAD) and paclitaxel against triple‐negative breast cancer cells},
journal = {Fundamental & Clinical Pharmacology},
year = {2024},
doi = {10.1111/fcp.13000}
}
EUVIMED